General Information of Drug (ID: DMQLNZC)

Drug Name
Empagli ozin Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Investigative [1]
Cross-matching ID
TTD Drug ID
DMQLNZC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dapagliflozin DM28UJG Non-insulin dependent diabetes 5A11 Approved [1]
Empagliflozin DMRF9YK Type-1 diabetes 5A10 Approved [1]
Canagliflozin DMFRM1I Non-insulin dependent diabetes 5A11 Approved [2]
PF-04971729 DM79VXT Type-2 diabetes 5A11 Approved [3]
Sotagliflozin DMMLXA9 Heart failure BD10-BD13 Approved [4]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO Type-2 diabetes 5A11 Approved [5]
ASP1941 DMGQ1TV Liver disease DB90-BD99 Phase 3 [6]
Remogliflozin etabonate DMW4YK1 Type-1/2 diabetes 5A10-5A11 Phase 2 [7]
LIK-066 DM32NWD Heart failure BD10-BD13 Phase 2 [8]
AVE-2268 DMA42BV Diabetic complication 5A2Y Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/glucose cotransporter 2 (SGLT2) TTLWPVF SC5A2_HUMAN Modulator [1]

References

1 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
2 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3 Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
4 LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.